Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 25, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number 001-38070 _________________ ...

Exhibit 99.1 NEWS RELEASE COMSTOCK ANNOUNCES THIRD QUARTER 2025 RESULTS AND CORPORATE UPDATES Fortifies Capital Base, Eliminates Debt Obligations and Funds Industry-scale Metals Launch VIRGINIA CITY, NEVADA, October 30, 2025 – Comstock Inc. (NYSE: LODE) ("Comstock," "our," and the "Company"), today announced its third quarter 2025 financial results, business updates and an updated 2025 business outlook. Recent Corporate Transactional and Liquidity and Capital Resources Highlights "In January, we communicate ...

Sales Performance - Q3 sales increased by 14.7% to $1.55 billion, with adjusted growth of 12.6% across all product groups[4] - TAVR sales reached $1.15 billion, growing 12.4% year-over-year, or 10.6% on a constant currency basis[5] - TMTT sales were $145.2 million, representing a year-over-year growth of 59.3%[8] - Net sales for Q3 2025 reached $1,553.1 million, a 14.7% increase from $1,354.4 million in Q3 2024[31] - Year-to-date sales for 2025 totaled $4,498.0 million, reflecting an increase of $444.3 million or 11.0% compared to the same period in 2024[45] - Sales in the United States for Q3 2025 were $907.5 million, a growth of $102.9 million or 12.8% year-over-year[45] - European sales increased by 21.3% to $387.9 million, up $68.1 million from Q3 2024[45] - Outside the United States, sales reached $645.6 million, representing a growth of 17.4% compared to the previous year[45] - The company reported a 59.8% increase in Transcatheter Mitral and Tricuspid Therapies year-to-date, with sales of $394.9 million[45] - Surgical Structural Heart sales for Q3 2025 were $258.0 million, an increase of $18.0 million or 7.5% from Q3 2024[45] Financial Metrics - Adjusted EPS for Q3 was $0.67, with a reported EPS of $0.50[4] - The company raised its full-year sales growth guidance to the high end of 9-10% and adjusted EPS guidance to $2.56 to $2.62[22] - The adjusted gross profit margin for Q3 was 77.9%, down from 80.7% in the same period last year[17] - Gross profit margin for Q3 2025 was 77.8%, down from 80.6% in Q3 2024[31] - The effective tax rate for Q3 2025 was 16.1%, compared to 10.1% in Q3 2024[31] - Basic earnings per share from continuing operations for Q3 2025 was $0.50, down from $0.61 in Q3 2024[31] - The adjusted net income for the same period was $389.9 million, with an adjusted EPS of $0.67, reflecting a profit margin of 27.5%[43] - For the nine months ended September 30, 2025, net sales reached $4,498.0 million, with a gross profit margin of 78.0% and a net income of $995.9 million, leading to an EPS of $1.70[44] - The adjusted net income for the nine months was $1,160.3 million, with an adjusted EPS of $1.98, indicating a profit margin of 28.3%[44] Expenses and Costs - SG&A expenses were $515 million, or 33.1% of sales, compared to $421 million, or 31.1% of sales last year[18] - R&D expenses increased to $281 million, reflecting strategic investments in the structural heart portfolio[19] - The company recorded certain litigation expenses of $90.4 million in Q3 2025, significantly higher than $10.8 million in Q3 2024[36] - Intangible assets impairment charges amounted to $40.0 million in Q3 2025, with no such charges in Q3 2024[38] - The company incurred certain litigation expenses of $90.4 million for the three months ended September 30, 2025, impacting the net income[43] - For the nine months ended September 30, 2025, litigation expenses totaled $116.8 million, which also affected the overall financial performance[44] Future Outlook - The company plans to project total sales for Q4 between $1.51 and $1.59 billion, with adjusted EPS of $0.58 to $0.64[22] - The company plans to continue focusing on litigation management and cost control to enhance future profitability and operational efficiency[43] - The company anticipates continued growth in the Implantable Heart Failure Management segment, with adjustments starting in September 2025[45]

Financial Performance - Consolidated revenue for Q3 2025 was $617.4 million, an increase of 8.4% compared to $569.4 million in Q3 2024[123] - Operating income for Q3 2025 reached $127.8 million, reflecting a 10.6% increase from $115.5 million in Q3 2024[123] - Operating margin improved to 20.7% in Q3 2025, up from 20.3% in Q3 2024, indicating a 0.4 percentage point increase[123] - Total revenue for the nine months ended September 30, 2025, was $1,804.4 million, a 7.1% increase from $1,684.1 million in the same period of 2024[123] - Operating income for the nine months ended September 30, 2025, was $367.0 million, representing a 15.9% increase from $316.6 million in the same period of 2024[123] - Adjusted operating income for Q3 2025 was $150.6 million, a 15.6% increase from $130.3 million in Q3 2024, while for the first nine months, it reached $429.4 million, up 15.4% from $372.1 million[146] Cash Flow and Investments - Cash provided by operating activities was $195.7 million in Q3 2025, a slight increase of 2.0% from $191.9 million in Q3 2024[123] - Free cash flow for Q3 2025 was $160.1 million, up 2.8% from $155.8 million in Q3 2024[123] - Cash used for investing activities in Q3 2025 was $(33.0) million, compared to $14.1 million in Q3 2024, indicating a significant change[123] - Cash used for financing activities increased to $(188.1) million in Q3 2025, up 212.5% from $(60.2) million in Q3 2024[123] - Cash provided by operating activities decreased by 12.0% to $385.7 million for the nine months ended September 30, 2025, compared to $438.2 million in the same period of 2024[202] - The company generated free cash flow of $160.1 million for the three months ended September 30, 2025, reflecting a 2.8% increase from $155.8 million in the same period of 2024[202] Revenue Breakdown - License-based revenue rose by 6.4% in Q3 2025, driven by strong demand for Morningstar Direct Platform and PitchBook products[131] - Asset-based revenue increased by 1.1% in Q3 2025, primarily due to growth in Morningstar Retirement products[132] - Transaction-based revenue surged by 27.2% in Q3 2025, mainly attributed to Morningstar Credit revenue[132] - Organic revenue increased by 9.0% in Q3 2025 and 8.0% in the first nine months of 2025, driven by growth in PitchBook, Morningstar Credit, and Morningstar Direct Platform[135] - International revenue accounted for 29% of consolidated revenue in Q3 2025, with a growth of 11.8% driven by Morningstar Credit and Morningstar Direct Platform products[138] Expenses - Total operating expenses for Q3 2025 were $490.1 million, reflecting an increase of 8.0% compared to the previous year[139] - Cost of revenue increased by $19.0 million in Q3 2025, primarily due to higher compensation expenses[140] - Sales and marketing expenses rose by $7.6 million in Q3 2025, driven by increased sales commissions and marketing costs[141] Shareholder Returns and Debt - The company declared a quarterly dividend of $0.455 per share, totaling $19.0 million, payable on October 31, 2025[195] - The company has a total outstanding debt of $499.8 million under the Amended 2022 Credit Agreement as of September 30, 2025, with borrowing availability of $500.0 million[190] - The company repurchased a total of 1,538,103 shares for $414.7 million under the 2022 Share Repurchase Program as of September 30, 2025, leaving $85.3 million available for future repurchases[197] Acquisitions and Future Plans - The company expects to complete the acquisition of the Center for Research in Security Prices, LLC for approximately $375.0 million during the fourth quarter of 2025[200] - The company paid $39.1 million for the acquisitions of DealX and Lumonic Inc. during the nine months ended September 30, 2025[199] Tax and Compliance - The effective tax rate for the three months ended September 30, 2025, was 25.5%, reflecting an increase of 5.7 percentage points compared to the same period in the prior year[183] - The company was in compliance with financial covenants, with consolidated funded indebtedness to consolidated EBITDA calculated at approximately 1.0x as of September 30, 2025[194] Currency and Market Position - The company has a net currency position of $41.9 million in Australian dollars as of September 30, 2025[208] - The estimated effect of a 10% adverse currency fluctuation on operating income for the nine months ended September 30, 2025, is a loss of $3.2 million from other foreign currencies[208]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________________________________________ FORM 10-Q _________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 814-00702 _________________________________________________ HERCULES CAPITAL, INC. (Exact Name of Registrant as Spec ...

Exhibit 99.1 AXT, Inc. Third Quarter 2025 Results October 30, 2025 Page 1 of 6 AXT, Inc. Announces Third Quarter 2025 Financial Results FREMONT, Calif., October 30, 2025 – AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor wafer substrates, today reported financial results for the third quarter, ended September 30, 2025. Management Qualitative Comments "This has been a highly active time for our business with the strong uptick in indium phosphide demand from data center application ...

Financial Performance - For the three months ended September 30, 2025, net income was $112.352 million, with adjusted earnings of $120.377 million[119]. - The diluted EPS for the same period was $1.94, while the adjusted EPS was $2.07[119]. - Tangible book value per common share increased to $45.22 as of September 30, 2025, compared to $39.22 a year earlier[120]. - Net income for the three months ended September 30, 2025, was $112,352 thousand, slightly up from $112,340 thousand for the same period in 2024, resulting in a diluted earnings per share of $1.94 compared to $1.93[123]. - The effective income tax rate decreased to 25.04% for the three months ended September 30, 2025, from 29.43% in the same period in 2024[137]. Asset and Liability Management - The Company has approximately $27.4 billion in assets and $43.0 billion of assets under custody and/or administration at Axos Clearing LLC[106]. - Total assets increased to $27,431,817 thousand as of September 30, 2025, up from $24,783,078 thousand as of June 30, 2025, and $23,569,084 thousand as of September 30, 2024, representing a year-over-year growth of 16.0%[121]. - Total liabilities increased by $2.5 billion or 11.5% to $24.6 billion at September 30, 2025, mainly due to higher deposit balances and secured financings from the Verdant acquisition[149]. - Stockholders' equity increased by $112.4 million to $2.793 billion at September 30, 2025, driven by net income for the quarter[158]. - The Company and Bank reported Tier 1 capital of $2,587,308, meeting all capital adequacy requirements and classified as "well capitalized" under regulatory standards[173]. Income and Expense Analysis - The Company generated non-interest income from various sources, including fees from loans originated for sale and deposit account service fees[106]. - Non-interest income increased by $3.7 million, or 13.0%, primarily due to higher banking and servicing fee income[134]. - Non-interest expense increased by $8.8 million, or 6.0%, primarily due to higher professional services and data processing expenses[135]. - The provision for credit losses was $17.3 million for the three months ended September 30, 2025, compared to $14.0 million for the same period in 2024[132]. Loan and Deposit Growth - Total deposits rose to $22,264,753 thousand as of September 30, 2025, compared to $20,829,543 thousand as of June 30, 2025, marking an increase of 6.9%[121]. - The company reported a growth in loans held for investment, net, to $1,585,527 thousand for the three months ended September 30, 2025, compared to $49,224 thousand for the same period in 2024, indicating strong loan demand[122]. - Total gross loans reached $23.1 billion at September 30, 2025, up from $21.6 billion at June 30, 2025, with Commercial & Industrial - Non-RE loans increasing to 34.5% of the portfolio[150]. - Total deposits increased by $1.4 billion or 6.9% to $22.3 billion at September 30, 2025, with significant growth in interest-bearing demand and savings accounts[154]. Capital Adequacy and Risk Management - Common equity tier 1 capital to risk-weighted assets was 11.66% as of September 30, 2025, down from 12.52% as of June 30, 2025, reflecting changes in capital adequacy ratios[121]. - The Company and Bank's common equity tier 1 capital ratio to risk-weighted assets was 11.66% as of September 30, 2025, exceeding the minimum requirement of 4.5%[170]. - The Company may need to raise additional capital to support further growth and maintain its "well capitalized" status[170]. - The Company and Bank were in compliance with the capital conservation buffer requirement, with minimums set at 7.0%, 8.5%, and 10.5% for common equity tier 1, tier 1, and total risk-based capital ratios, respectively[174]. Interest Rate Sensitivity - The sensitivity of net interest income to a 200 basis points increase is projected to be a 6.7% change in the first 12 months and 12.5% in the next 12 months[182]. - A 100 basis points increase in interest rates is expected to result in a 3.5% change in net interest income for the first 12 months and 6.2% for the next 12 months[182]. - The market value of equity (MVE) is projected to increase by 4.7% with a 200 basis points rise in interest rates[183]. - A 100 basis points increase in interest rates is expected to lead to a 3.2% increase in MVE[183]. Business Segments Overview - The Banking Business Segment focuses on online banking, mortgage, vehicle, and unsecured lending, serving consumers and small businesses nationwide[113]. - The Securities Business Segment includes clearing broker-dealer and registered investment advisor custody businesses, offering products to both independent customers and Banking Business Segment clients[114]. - The Banking Business Segment's net interest income decreased by $1.3 million, or 0.4%, compared to the same period in 2024[141]. - The Securities Business Segment's net interest income increased by $0.9 million, or 12.8%, compared to the same period in 2024[146]. Credit and Interest Rate Risk - Credit risk in the Securities Business Segment arises from potential non-performance by counterparties, customers, or issuers of securities[187]. - The company conducts periodic credit reviews and monitors position limits for each counterparty to manage credit risk[188]. - Collateral for margin loans and securities lending activities is marked to market daily, with adjustments made as necessary[188]. - The Securities Business Segment is primarily exposed to interest rate risk from interest-earning assets and funding sources, including customer and correspondent cash balances[185].

Exhibit 99.2 Quarterly Financial Supplement Third Quarter 2025 (Unaudited) World Headquarters Internet Address Contacts 16600 Swingley Ridge Road www.rgare.com Axel André Chesterfield, Missouri 63017 U.S.A. Executive Vice President and Chief Financial Officer Phone: (636) 736-7000 e-mail: Axel.Andre@rgare.com Reinsurance Group of America, Incorporated 3rd Quarter 2025 Table of Contents | Consolidated | | | --- | --- | | Financial Highlights | 3 | | Consolidated GAAP Income Statements (including Adjusted Ope ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Exact Name of Registrant as Specified in Its Charter) ____________________________________________________ ____________________________________________________ FORM 10-Q ____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Exhibit 99.1 303 International Circle P: 410.427.1700 Suite 200 Hunt Valley, MD 21030 PRESS RELEASE – FOR IMMEDIATE RELEASE OMEGA REPORTS THIRD QUARTER 2025 RESULTS AND RECENT DEVELOPMENTS Completed $978 Million in New Investments Year-to-Date Closed a New $2.3 Billion Unsecured Credit Facility Increased Full Year Adjusted FFO Guidance Repaid $600 Million of Senior Unsecured Notes in Q4 HUNT VALLEY, MARYLAND – October 30, 2025 – Omega Healthcare Investors, Inc. (NYSE: OHI) (the "Company" or "Omega") announc ...